[1] Creaven PJ, Pendyala L, Meropol NJ, et al. Initial clinical trial and pharmacokinetics of thymitaqTM by 10- day continuous infusion in patients with advanced solid tumors[J]. Cancer Chemother Pharmacol, 1998, 41: 167-70. [2] Mok TSK, Leung TWT, Lee SD, et al. A multi-centre randomized phase Ⅱ study of nolatrexed versus doxorubicin in treatment of Chinese patients with advanced hepatocellular carcinoma[J]. Cancer Chemother Pharmacol, 1999, 44:307-11. [3] Pivot X, Wadler S, Kelly C, et al. Result of two randomized trials comparing nolatrexed (Thymitaq) versus methotrexate in patients withrecurrentheadandneckcancer[J]. AnnOncol, 2001,12:1595-9. [4] Nomura T, Nakagawa M, Fujita Y, et al. Clinical significance of thymidylate synthase expression in bladder cancer[J]. Int J Urol, 2002,9: 368-76. [5] Chu E, Koeller DM, Casey JL, et al. Autoregualtrion of human thymidylate synthase messenger RNA translation by thymidylate synthase[J]. Proc Natl Acad Sci USA, 1991, 88: 8977-81. [6] Chu E, Koeller DM, Johnston PG, Regulation of thymidylate synthase in human colon cancer cells treated with 5-fluorouracil and interferon-gamma[J]. Mol Pharmacol, 1993, 43: 527-33. [7] Swain SM, Lippman ME, Egan EF, et al. Fluorouracil and highdose leucovorin in previously treated patients with metastatic breast cancer[J]. J Clin Oncol, 1989, 7: 890-9. [8] Estlin E J, Balmanno K, Calvert AH, et al. The relationship between intrinsic thymidylate synthase expression and sensitivity to THYMITAQ in human leukaemia and colorectal carcinoma cell lines[J].Br J Cancer, 1997, 76(12): 1579-85. [9] Shaw D, Berger FG, Spencer HT. Retroviral expression of Escherichia coli thymidylate synthase cDNA confers high-level antifolate resistance to hematopoietic cells[J]. Hum Gene Ther, 2001, 12: 51-9. [10] Triest BV, Pinedo HM, Hensbergen YV, et al. Tymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but for folate-based thymidylate synthase inhibitor, in 13nonselected colon cancer cell lines[J]. Clin Cancer Res, 1999, 5:643-54. |